Fibrinogen-like protein 2 (FGL2), also known as fibroleukin, is a multifunctional immune checkpoint playing a pivotal role in tumor immunosuppression, microvascular coagulation, and fibrotic diseases. Existing in both membrane-bound (mFGL2) and soluble secreted (sFGL2) forms, FGL2 acts as an effector of regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), making it a highly sought-after target for next-generation cancer immunotherapy and anti-fibrotic drug development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FGL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGL2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View FGL2 Products |
| Gene Delivery | FGL2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for cell-surface mFGL2 expression and functional assays. |
View FGL2 Products |
| Benchmark Ab | Anti-FGL2 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View FGL2 Products |
| Validator | FGL2 siRNA Set For target knockdown verification and specificity controls in cell-based assays. |
View FGL2 Products |
| Related Target A | FCGR2B (Fc gamma RIIB) The primary inhibitory receptor for soluble FGL2 (sFGL2), mediating immunosuppressive signaling. |
View FCGR2B Products |
| Related Target B | PDCD1 (PD-1) Synergistic immune checkpoint. FGL2 upregulation is a known mechanism of resistance to anti-PD-1 therapy. |
View PDCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Form-Specific Targeting (sFGL2 vs. mFGL2) | Soluble recombinant FGL2 (oligomeric state preserved) and Lentivirus-driven stable cell lines expressing full-length membrane FGL2 are available. |
| Cross-Species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus FGL2 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives in Binding Assays | Validated siRNA sets included for target knockdown specificity verification in functional assays. |
Live FGL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FGL2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and combination strategies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual blockade of FGL2 and established checkpoint pathways like PD-1/PD-L1 to overcome cold tumor microenvironments and anti-PD-1 resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutions, Biotech Startups | Glioblastoma (GBM), Hepatocellular Carcinoma (HCC) | Recombinant FGL2 antigen with native glycosylation (HEK293) for high-affinity screening. |
| Bispecific Antibody (bsAb) | Oncology-focused Biopharma | Solid Tumors (Cold Tumors) | Dual-binding validation requiring high-purity FGL2 and partner antigens (e.g., PD-L1). |
| Small Molecule Inhibitors | Preclinical Discovery Programs | Thrombotic Disorders, Inflammatory Fibrosis | Activity/coagulation assays using stable cell lines (Lentivirus-transduced mFGL2). |